Skip to content

The study of circulating RNA applied as prospective surveillance and pre-clinical screening biomarker for HCC in high-risk population

The study of circulating RNA applied as prospective surveillance and pre-clinical screening biomarker for HCC in high-risk population

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCD-15007220
Enrollment
Unknown
Registered
2015-05-22
Start date
2015-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Gold Standard:
Index test:

Sponsors

International Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18 and older, less than 80 years old; Men and women there is no limit; (2) Patients with chronic hepatitis B (CHB); (3) Blood coagulation function index within the normal range, exceptional cases (judging by the doctor) that has deviation from standard area is acceptable; (4) Subjects (or their legal representatives) have signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Serious hemodynamic instability; (2) Patients or its authorized person is not willing to sign a written informed consent or unwilling to comply with the scheme; (3) Pregnant woman; (4) No autonomous decision-making ability or mental illness patients; (5) Patients who has serious heart, brain, liver and kidney system disease.

Design outcomes

Primary

MeasureTime frame
Circulating RNA;alpha-fetoprotein;liver function;five serological markers of hepatitis b;Liver ultrasound test;

Countries

China

Contacts

Public ContactHongyang Wang
hywangk@vip.sina.com+86 021-81875361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026